Pathological Scenario with the Mannose-Binding Lectin in Patients with IgA Nephropathy
被引:15
|
作者:
Ohsawa, Isao
论文数: 0引用数: 0
h-index: 0
机构:
Juntendo Univ, Div Nephrol, Dept Internal Med, Fac Med, Tokyo 1138421, JapanJuntendo Univ, Div Nephrol, Dept Internal Med, Fac Med, Tokyo 1138421, Japan
Ohsawa, Isao
[1
]
Ishii, Masaya
论文数: 0引用数: 0
h-index: 0
机构:
Juntendo Univ, Div Nephrol, Dept Internal Med, Fac Med, Tokyo 1138421, JapanJuntendo Univ, Div Nephrol, Dept Internal Med, Fac Med, Tokyo 1138421, Japan
Ishii, Masaya
[1
]
Ohi, Hiroyuki
论文数: 0引用数: 0
h-index: 0
机构:
Juntendo Univ, Div Nephrol, Dept Internal Med, Fac Med, Tokyo 1138421, JapanJuntendo Univ, Div Nephrol, Dept Internal Med, Fac Med, Tokyo 1138421, Japan
Ohi, Hiroyuki
[1
]
论文数: 引用数:
h-index:
机构:
Tomino, Yasuhiko
[1
]
机构:
[1] Juntendo Univ, Div Nephrol, Dept Internal Med, Fac Med, Tokyo 1138421, Japan
A deeper understanding of the mechanism of complement activation may help to elucidate the pathogenesis of IgA nephropathy (IgAN). Traditionally, the activation of an alternative pathway (AP) has been recognized as an enhancer mechanism of glomerular damage. This paper documents contemporary information concerning the possible pathological mechanisms of the lectin pathway (LP) in the circulation and in the glomerulus. The circulating initiator of LP activation is not fully understood. However, ligands for mannose-binding lectin (MBL) which are among the starter molecules of the LP are aberrant glycosylated molecules-containing immune complex. Recent reports have focused on N-glycans on secretory IgA as a candidate ligand. Mesangial deposits of MBL are seen in 25% of patients with IgAN. Mesangial deposits of MBL and C4 and/or C4 breakdown products are implicated as markers for disease progression of IgAN. On the other hand, patients with MBL deficiency tend to show better clinical presentation and lower levels of urinary protein and serum creatinine than MBL-sufficient patients. It is now recognized that involvement of AP and LP constitutes an additional mechanism for explaining the progression of IgAN.
机构:
Evangel Hosp, Rheumatol Unit, Curitiba, Parana, BrazilEvangel Hosp, Rheumatol Unit, Curitiba, Parana, Brazil
Skare, Thelma L.
Nisihara, Renato
论文数: 0引用数: 0
h-index: 0
机构:
Evangel Hosp, Rheumatol Unit, Curitiba, Parana, Brazil
Posit Univ, Dept Med, Rua Prof Pedro Viriato Parigot de Souza 5300, BR-81180330 Curitiba, Parana, BrazilEvangel Hosp, Rheumatol Unit, Curitiba, Parana, Brazil
Nisihara, Renato
Cieslinski, Juliana Z.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Fed Parana, Dept Clin Anal, Curitiba, Parana, BrazilEvangel Hosp, Rheumatol Unit, Curitiba, Parana, Brazil
Cieslinski, Juliana Z.
Zeni, Joao O.
论文数: 0引用数: 0
h-index: 0
机构:
Evangel Hosp, Rheumatol Unit, Curitiba, Parana, BrazilEvangel Hosp, Rheumatol Unit, Curitiba, Parana, Brazil
Zeni, Joao O.
Rasera, Henrique N.
论文数: 0引用数: 0
h-index: 0
机构:
Evangel Hosp, Rheumatol Unit, Curitiba, Parana, BrazilEvangel Hosp, Rheumatol Unit, Curitiba, Parana, Brazil
Rasera, Henrique N.
Messias-Reason, Iara
论文数: 0引用数: 0
h-index: 0
机构:
Univ Fed Parana, Dept Clin Anal, Curitiba, Parana, BrazilEvangel Hosp, Rheumatol Unit, Curitiba, Parana, Brazil
Messias-Reason, Iara
Utiyama, Shirley R. R.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Fed Parana, Dept Clin Anal, Curitiba, Parana, BrazilEvangel Hosp, Rheumatol Unit, Curitiba, Parana, Brazil
机构:
Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USAMerck Res Labs, BRIE Franchise, Rahway, NJ 07065 USA
Ip, W. K. Eddie
Takahashi, Kazue
论文数: 0引用数: 0
h-index: 0
机构:
Harvard Univ, Sch Med, Dept Pediat, Lab Dev Immunol,Massachusetts Gen Hosp, Boston, MA 02115 USAMerck Res Labs, BRIE Franchise, Rahway, NJ 07065 USA
Takahashi, Kazue
Ezekowitz, R. Alan
论文数: 0引用数: 0
h-index: 0
机构:
Merck Res Labs, BRIE Franchise, Rahway, NJ 07065 USAMerck Res Labs, BRIE Franchise, Rahway, NJ 07065 USA
Ezekowitz, R. Alan
Stuart, Lynda M.
论文数: 0引用数: 0
h-index: 0
机构:
Harvard Univ, Sch Med, Dept Pediat, Lab Dev Immunol,Massachusetts Gen Hosp, Boston, MA 02115 USAMerck Res Labs, BRIE Franchise, Rahway, NJ 07065 USA